前瞻性II期TheraP试验中基于PSMA PET的入组标准对接受PSMA靶向放射性配体治疗的转移性去势抵抗性前列腺癌患者的影响
本研究回顾性分析107例接受PSMA放射性配体治疗的转移性去势抵抗性前列腺癌患者,按是否满足TheraP试验的PSMA PET入组标准分组。满足标准组PSA缓解率54.5%高于不满足组20%(P=0.0012),中位PSA无进展生存和总生存均显著更长。采用不同SUVmax阈值对单个最热病灶的预后无影响。
要点
- 满足TheraP PSMA PET入组标准者PSA缓解率54.5% vs 不满足者20%(P=0.0012)。
- 满足标准组中位PSA无进展生存(P=0.007)和总生存(P=0.0007)均显著更长。
- 不满足TheraP标准者仍有相当比例出现治疗反应。
核心结论
- 按TheraP入组标准选择患者可使该预选队列获得更好的治疗反应和结局,但相当数量不满足标准者也有较高缓解率。
研究设计与样本
- 回顾性分析107例接受PSMA放射性配体治疗的转移性去势抵抗性前列腺癌患者,按是否满足TheraP的PSMA PET入组标准分为阳性组77例和阴性组30例,本组患者未行18F-FDG PET。
主要发现
- TheraP cePSMA PET阳性组PSA缓解率54.5% vs 阴性组20%(P=0.0012)。
- TheraP cePSMA PET阳性组中位PSA无进展生存显著长于阴性组(P=0.007),中位总生存也显著更长(P=0.0007)。
- TheraP cePSMA PET阳性组是更长总生存的显著预后因素(P=0.003)。
- 对单个最热病灶采用不同于TheraP的预设SUVmax阈值对适合PSMA放射性配体治疗患者的结局无影响。
关键数值与推荐
- TheraP入组标准包括治疗前68Ga-PSMA-11 PET显示按预设阈值肿瘤摄取充分,且无18F-FDG阳性而PSMA配体阴性的肿瘤病灶。
- PSA缓解定义为PSA较基线下降≥50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本组患者未行18F-FDG PET,与TheraP试验不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has shown encouraging results for treatment of metastatic castration-resistant prostate cancer (mCRPC) in the prospective, multicenter, randomized phase II TheraP study. The inclusion criteria for that study comprised a pretherapeutic 68Ga-PSMA-11 PET scan showing sufficient tumor uptake using a predefined threshold and the absence of 18F-FDG-positive, PSMA ligand-negative tumor lesions. However, the prognostic value of these PET-based inclusion criteria remains unclear. Therefore, we evaluated the outcome of mCRPC patients treated with PSMA RLT using TheraP as well as other TheraP-based PET inclusion criteria. Methods: First, patients were dichotomized into 2 groups whose PSMA PET scans did (TheraP contrast-enhanced PSMA [cePSMA] PET-positive) or did not (TheraP cePSMA PET-negative) fulfill the inclusion criteria of TheraP. Notably, unlike in TheraP, 18F-FDG PET was not performed on our patients. Prostate-specific antigen (PSA) response (PSA decline ≥ 50% from baseline), PSA progression-free survival, and overall survival (OS) were compared. Additionally, patients were further dichotomized according to predefined SUVmax thresholds different from those used in TheraP to analyze their potential impact on outcome as well. Results: In total, 107 mCRPC patients were included in this analysis (TheraP cePSMA PET-positive, n = 77; TheraP cePSMA PET-negative, n = 30). PSA response rates were higher in TheraP cePSMA PET-positive patients than in TheraP cePSMA PET-negative patients (54.5% vs. 20%, respectively; P = 0.0012). The median PSA progression-free survival (P = 0.007) and OS (P = 0.0007) of patients were significantly longer in the TheraP cePSMA PET-positive group than in the TheraP cePSMA PET-negative group. Moreover, being in the TheraP cePSMA PET-positive group was identified as a significant prognosticator of longer OS (P = 0.003). The application of different SUVmax thresholds for a single hottest lesion demonstrated no influence on outcome in patients eligible for PSMA RLT. Conclusion: Patient selection for PSMA RLT according to the inclusion criteria of TheraP led to a better treatment response and outcome in our preselected patient cohort. However, a relevant number of patients not fulfilling these criteria also showed substantial rates of response.
引用
- Karimzadeh A, Heck M, Tauber R, et al. The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy. J Nucl Med. 2023. PMID: 37290796. doi:10.2967/jnumed.122.265346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。